ReviewCurrent neurology and neuroscience reports2004
Malignant gliomas.
Review in Current neurology and neuroscience reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- U87MG glioma cells overexpressing IL-17 acclerate early-stage growthOncology letters · 2013Article
- Article
- Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Expert opinion on therapeutic targets · 2011Review
- Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
- Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Expert review of neurotherapeutics · 2009Review
- cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor [alpha]2 chain.Cancer immunology, immunotherapy : CII · 2009Article
- Immunotherapeutic approaches for glioma.Critical reviews in immunology · 2009Review
- Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.Journal of translational medicine · 2007Article
- Targeted molecular therapy of malignant gliomas.Current oncology reports · 2006Article
- EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.Neoplasia (New York, N.Y.) · 2005Article
- Targeted molecular therapy of malignant gliomas.Current neurology and neuroscience reports · 2005Review
- Signal transduction mechanisms involved in the proliferation of C6 glioma cells induced by lysophosphatidic acid.Neurochemical research · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are the most common type of primary brain tumor. Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies.
Indexed as
Identifiers
15102348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.